Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2500396 | 1.00 | HSD11B1 (0.47) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL23265405 | 0.80 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL3973620 | 0.78 | HSD11B1 (0.49) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL12794680 | 0.78 | HSD11B1 (0.49) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL22371748 | 0.78 | MMP13 (0.44) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL20765293 | 0.78 | HSD11B1 (0.51) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL30661336 | 0.78 | HSD11B1 (0.51) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL16499643 | 0.76 | HSD11B1 (0.47) | HSD11B1CHRM2CHRM1CHRM3MMP13 | |
| SCHEMBL12190746 | 0.76 | MMP13 (0.42) | HSD11B1MMP13GPR119KMT2AMEN1 | |
| SCHEMBL23265404 | 0.74 | MMP13 (0.44) | HSD11B1MMP13GPR119KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | HSD11B1 2519/4885CHRM2 47/4885CHRM1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.